Processing the samples through a 100 KDa size exclusion column followed by absorption with protein A/G beads, which depleted IgG by >99.99%, eliminated the ability of the samples to cleave the ACE2 peptide substrate, supporting the hypothesis that a fraction of COVID-19 patients may develop antibodies that have ACE2 substrate cleavage activity. This evidence concerns the gene ACE2 and COVID-19.